UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September~~ 22October 04, 2024

America Great Health

(Exact name of registrant as specified in charter)

~~Wyoming~~wyoming

(State or other jurisdiction of incorporation)

0-27873		98-0178621
(Commission File Number)		(IRS Employer Identification No.)
1609 W Valley Blvd., #338, Alhambra, CA		91803
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (626) 576-1299

1609 W Valley Blvd., #338, Alhambra, CA 91803		28277
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (626) 576-1299

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class Trading Symbol(s) Name of each exchange on which registered N/A N/A N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Item~~Securities ~~1.01.~~registered ~~Entry~~pursuant ~~into~~to aSection ~~material~~12(b) ~~definitive~~of ~~agreement~~the Act:

OnTitle ~~September~~of ~~22,~~each ~~2024,~~class ~~America~~Trading ~~Great Health~~ Symbol(~~the “Company”~~s) ~~entered~~Name into a Framework Agreement for Product Project Cooperation (the “Contract”) with Xinjiang Wuse Guoshan Supply Chain Management, Co. Ltd., a Chinese company (“Xinjiang Wuse”). The Company’s products are a series of ~~ion~~each ~~peptide~~exchange products developed using “protein surface ion modification technology,” achieving a world-leading position in both research and production. Xinjiang Wuse, with its strategic location in Xinjiang, China, has the advantageous resources based on ~~the~~which homology of medicine and food in Xinjiang, and has built a supply chain operation platform for medicine and food from the same source of supply base, product selection center, distribution center and urban warehouse.registered

Under the Contract, the high-end biotechnology products developed and produced by the Company are consistent with Xinjiang Wuse's product system and will be implanted into its marketing network system as high-end products in the city warehouseItem 5.02 Departure ~~The~~of ~~Company~~Directors ~~guarantees~~or ~~that~~Principal ~~its~~Officers; ~~products~~Election ~~have~~of ~~relevant~~Directors; ~~compliance~~Appointment ~~qualifications to enter the Chinese market. Xinjiang Wuse designs and distributes marketing channel plans suitable for the Company's products based on the needs~~ of ~~each~~Principal ~~city's warehouse area.~~Officers

~~SIGNATURES~~On June 2nd, 2025, the Company accepted the resignation of Quinn Chen as Chief Financial Officer of the Company to be effective June 30, 2025. Mr. Chen is resigning for personal reasons and there were no disagreements between him and the Company. His departure is not related to the operations, policies or practices of the Company or any issues regarding accounting policies or practices.

~~Pursuant~~The Board toof ~~the~~Directors ~~requirements~~ of the ~~Securities~~Company ~~Exchange~~intends ~~Act~~to conduct a search of ~~1934~~potential internal and external candidates to replace Mr. Chen. In the interim, the ~~registrant~~Company’s ~~has~~President ~~duly~~and ~~caused~~Chief Executive Officer, ~~this~~Mike ~~report~~Wang, towill beserve ~~signed~~as bythe Chief Financial Officer, to assume the ~~undersigned~~duties as ~~hereunto~~principal ~~duly~~financial ~~authorized~~officer and principal accounting officer of the Company.

~~AMERICA GREAT HEALTH~~1

~~Date: October 25, 2024~~SIGNATURES

~~By: /s/~~Pursuant to ~~Mike~~the ~~Wang~~ requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.

Name: Mike Wang

	AMERICA GREAT HEALTH

Date: September 12, 2025	By:	/s/ Mike Q. Wang
	Name:	Mike Q. Wang
	Title:	President/CFO

~~Title: President~~2

false 0001098009 true 0001098009 2024-09-22 2024-09-22

Filing Compare · America Great Health